Register by Friday, November 18th and Save up to $200! ----------------------------------------------------------------------------------- THE PLASMA PROTEOME: High Abundance Vs. Low Abundance Discovering Biological Markers for Diagnostics and Drug Discovery
January 10-11, 2006 | Hotel Del Coronado | San Diego, CA ----------------------------------------------------------------------------------- 4 Register Today
4 View Agenda (No download form required)
4 Submit a Poster Save $50
Don't Miss aNEW! PepTalk Partnering Forum View Agenda aInteractive Panel Discussions aBuzZ Session Round tables Submit a Topic aPoster Competition aOver 50 Exhibitors Showcasing the Latest Technology View Current List of Exhibitors -----------------------------------------------------------------------------------
Kick Off Keynote Presentation
Challenges in the Analysis of Complex Specimens Dr. John R. Yates, III, Professor of Cell Biology, Scripps Research Institute
Challenges of High Abundance Plasma Proteins
Highlights of the HUPO Plasma Proteome Project Dr. Gilbert S. Omenn, Professor of Internal Medicine, Human Genetics, and Public Health, University of Michigan, Leader, HUPO Plasma Protein Project
Serum Proteomic Standards Dr. Peter E. Barker, Principal Investigator & Biologist, NIST
Blood Samples for Proteomics: Don't Overlook Step One of Plasma Proteomics Dr. Craig Gelfand, Director, Growth Technologies, Preanalytical Systems, BD Biosciences
Digging Deeper into the Proteome
Peptidomics Approaches for Low-Abundance Biomarker Detection in Blood Plasma from Clinical Trials Dr. Peter Schulz-Knappe, Chief Scientific Officer, BioVisioN AG
Integration of Combinatorial Chemistry and Affinity Chromatography Provides a Powerful Platform for Proteomics and New Product Discovery Dr. David J. Hammond, Executive Director Plasma Derivatives, Holland Laboratory, American Red Cross
Development of a "Reverse Capture" Microarray for Studies of Antigen-Autoantibody Reactivity Dr. Brian Liu, Assistant Professor, Urology, Brigham and Women's Hospital, Harvard Medical School
Biomarker Discovery
Candidate-Based Approach to Biomarker Development Dr. N. Leigh Anderson, Chief Executive Officer, Plasma Proteome Institute
Clinical Plasma Profiling to Identify and Sequence Proteins that Differentiate Anti-Hypertensives Dr. Gregory J. Opiteck, Director, Protein Analysis, Caprion Pharmaceuticals, Inc.
CSF and Plasma-Based Protein Biomarkers for Motor Neuron Disease Dr. Robert Bowser, Associate Professor, Pathology, University of Pittsburgh
The Plasma Proteome in Sepsis: Toward Dynamic, Data-Driven Disease Management Dr. Stephen F. Kingsmore, President, National Center for Genome Resources
A Novel Platform for Serum Biomarker Discovery and Validation for Application in Cancer Diagnosis Mr. David Deems, Vice President, Product Integration and Operations, Predicant Biosciences
Towards Comprehensive Proteomic Mapping of Blood Vessels through Prefractionation and Multi-modal MS Analysis Dr. Jan E. Schnitzer, Scientific Director, Professor of Cellular & Molecular Biology, Director of Vascular Biology & Angiogenesis Program, Sidney Kimmel Cancer Center
Identification of Proteotypic N-linked Glycopeptides for Serum Biomarker Discovery Dr. Hui Zhang, Senior Research Scientist, Serum Biomarker Discovery Group, Institute for Systems Biology
HUPO Initiatives for Biomarker Discovery: Opportunities and Challenges Dr. Samir Hanish, Director, Molecular Diagnostics Program; Member, Fred Hutchinson Cancer Research Center ----------------------------------------------------------------------------------- Corporate Sponsors:
Beckman Coulter Inc. Bruker Daltonics Biacore Decision Biomarkers GenTel INCAPS Invitrogen Nautilus Biotech NextGen Sciences Nonlinear Dynamics Pall Life Sciences Promega Corporation QIAGEN, Inc. Whatman
For Sponsorship and Exhibit Information contact: Arnold Wolfson at 617-630-1331 or awolfson@healttech.com ----------------------------------------------------------------------------------- To Register and for more information, visit www.chi-PepTalk.com
|